APA (7th ed.) Citation

I, N., C, F., P, M., V, K., M, T., E, K., . . . M, G. (2025). The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Leukemia, 39(9), 2226. https://doi.org/10.1038/s41375-025-02677-5

Chicago Style (17th ed.) Citation

I, Ntanasis-Stathopoulos, Filippatos C, Malandrakis P, Koutoulidis V, Trapali M, Kastritis E, Terpos E, Dimopoulos MA, and Gavriatopoulou M. "The Impact of High-risk Cytogenetics on Treatment Efficacy and Outcomes of Patients with Relapsed/refractory Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials." Leukemia 39, no. 9 (2025): 2226. https://doi.org/10.1038/s41375-025-02677-5.

MLA (9th ed.) Citation

I, Ntanasis-Stathopoulos, et al. "The Impact of High-risk Cytogenetics on Treatment Efficacy and Outcomes of Patients with Relapsed/refractory Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials." Leukemia, vol. 39, no. 9, 2025, p. 2226, https://doi.org/10.1038/s41375-025-02677-5.